Our portfolio company Nordic Nanovector shows continued progress in clinical development programmes with Betalutin® in their first quarter 2017 presentation. Luigi Costa, CEO of Nordic Nanovector, comments: “In the first quarter of 2017 we continued the positive momentum of 2016. I am pleased to report the excellent progress Nordic Nanovector is making to advance its clinical […]
Our portfolio company Photocure reported a Hexvix/Cysview revenue growth of 9% to NOK 36.5 million in the first quarter of 2017 (Q1 2016: NOK 33.5), with an EBITDA of NOK 4.9 million for the Hexvix/Cysview commercial franchise. The company reported a growth of 32% for the important US market, were the company recently unveiled the […]
Targovax is a clinical stage company focused on developing immuno-oncology therapies to target solid tumors. On april 25th, the company announced its first quarter 2017 results. HIGHLIGHTS FOR THE FIRST QUARTER 2017: Targovax announced encouraging top line two-year survival data from the phase I/II TG01 clinical trial in resected pancreatic cancer patients – 68% […]
OncoImmunity AS was ranked fourth out of 250 applicants for the EU SME Instrument grant. OncoImmunity is one of the portfolio companies of the Radium Hospital Research Foundation and is developing innovative software solutions to guide the discovery of neoantigen-based personalized immunotherapies and biomarkers. “We applied for the SME instrument grant as it represents an […]
Our portfolio company Targovax ASA has announced its fourth quarter and full year 2016 results.
Radforsk porfolio company Photocure reported a revenue growth of 10 % to NOK 38.1 million in the fourth quarter of 2016.
Our portfolio company Oncoinvent announced today the closing of a 210 MNOK (approx. 25 MUSD) private placement of ordinary shares. Financing will support development of Radspherin™, a novel radiotherapeutic treatment for peritoneal carcinomatosis. Large privately owned investment companies joining the Company as new investors include Geveran Trading Co. Ltd., Canica AS, CGS Holding AS, Helene […]
Our portfolio company PCI Biotech has been granted NOK 13.8 million to the project “Photochemical vaccination – novel immunotherapy concept for treatment of cancer and infectious diseases”. The main goal of the project is to document in a proof-of-principle clinical study in cancer patients that PCI Biotech’s photochemical internalization (PCI) technology can be used […]
The grant will be used to develop a software framework to predict the peptides that confer maximum immunogenicity with minimum autoimmune side-affects to a patient.